Stay updated with breaking news from Enrollment Complete. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Tivic Health Systems, Inc. announced it has initiated the second phase of its clinical work to advance its novel non-invasive cervical vagus nerve stimulation . The company has entered into a...
- In Phase 1/2 ACHIEVE Trial, DYNE-101 Demonstrated Dose Dependent 27% Mean Splicing Correction Across All Patients in the 5.4 mg/kg Cohort at 3 Months - - DYNE-101 Showed Improvement in Myotonia,...
- In Phase 1/2 ACHIEVE Trial, DYNE-101 Demonstrated Dose Dependent 27% Mean Splicing Correction Across All Patients in the 5.4 mg/kg Cohort at 3 Months - ...
- In Phase 1/2 ACHIEVE Trial, DYNE-101 Demonstrated Dose-Dependent Splicing Correction, Muscle Delivery and DMPK Knockdown - - All Evaluable Patients in the 3.4 mg/kg Cohort Treated with DYNE-101...
- In Phase 1/2 ACHIEVE Trial, DYNE-101 Demonstrated Dose-Dependent Splicing Correction, Muscle Delivery and DMPK Knockdown -